CARsgen Therapeutics Holdings Ltd. (HK:2171)
:2171
Want to see HK:2171 full AI Analyst Report?
Top Page
CARsgen Therapeutics Holdings Ltd.
(2171)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$26.00
▲(74.61% Upside)
Action:ReiteratedDate:04/15/26
The score is held back primarily by weak financial performance—persistent operating losses, continued net losses, and significant negative operating cash flow—despite improved revenue traction. Technicals are a key positive with strong trend and momentum signals, while valuation is pressured by the negative P/E and lack of dividend support.
Positive Factors
Revenue momentum & positive gross profit
Material revenue growth alongside a shift to positive gross profit indicates the company is beginning to monetize its pipeline and capture product economics. This structural improvement can support future margin expansion and reduce incremental funding needs as commercial traction and manufacturing scale persist.
Negative Factors
Deep negative operating cash flow
Persistent, large negative operating cash flow means the business cannot self-fund operations or growth, creating structural reliance on external financing. This increases dilution and may constrain timing of clinical programs or commercial investment absent durable improvement in cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue momentum & positive gross profit
Material revenue growth alongside a shift to positive gross profit indicates the company is beginning to monetize its pipeline and capture product economics. This structural improvement can support future margin expansion and reduce incremental funding needs as commercial traction and manufacturing scale persist.
Read all positive factors
CARsgen Therapeutics Holdings Ltd. (2171) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$13.98B
Dividend YieldN/A
Average Volume (3M)1.98M
Price to Earnings (P/E)―
Beta (1Y)1.51
Revenue Growth219.26%
EPS Growth87.63%
CountryHK
Employees465
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding578,130,500
10 Day Avg. Volume1,760,508
30 Day Avg. Volume1,977,652
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)9.40
Price to Sales (P/S)60.15
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$25.70Price Target Upside72.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.47
Revenue Forecast (FY)HK$1.10B
CARsgen Therapeutics Holdings Ltd. Business Overview & Revenue Model
Company Description
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in Chin...
How the Company Makes Money
null...
CARsgen Therapeutics Holdings Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
62
Positive
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 122.41M | 39.42M | 0.00 | 0.00 | 25.81M |
| Gross Profit | 49.15M | 14.75M | -96.57M | -94.81M | 25.81M |
| EBITDA | -200.42M | -686.61M | -717.64M | -748.73M | -4.67B |
| Net Income | -95.33M | -798.13M | -747.79M | -892.25M | -4.74B |
Balance Sheet | |||||
| Total Assets | 1.29B | 1.67B | 2.26B | 2.76B | 3.51B |
| Cash, Cash Equivalents and Short-Term Investments | 1.12B | 1.48B | 1.85B | 2.27B | 3.01B |
| Total Debt | 61.20M | 166.42M | 85.22M | 119.44M | 338.05M |
| Total Liabilities | 513.02M | 616.33M | 455.51M | 289.64M | 508.98M |
| Stockholders Equity | 783.65M | 1.06B | 1.80B | 2.47B | 3.00B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -429.26M | -464.48M | -781.66M | -690.77M |
| Operating Cash Flow | -230.77M | -409.69M | -454.94M | -643.05M | -512.32M |
| Investing Cash Flow | -2.81M | 12.52M | 39.25M | 2.39B | -2.47B |
| Financing Cash Flow | -108.83M | 18.46M | -22.14M | -236.51M | 2.67B |
CARsgen Therapeutics Holdings Ltd. Technical Analysis
Positive
14.89
Price Trends
15.90
Positive
16.04
Positive
18.22
Positive
Market Momentum
2.01
Negative
82.01
Negative
94.76
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2171, the sentiment is Positive. The current price of 14.89 is below the 20-day moving average (MA) of 18.19, below the 50-day MA of 15.90, and below the 200-day MA of 18.22, indicating a bullish trend. The MACD of 2.01 indicates Negative momentum. The RSI at 82.01 is Negative, neither overbought nor oversold. The STOCH value of 94.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2171.
CARsgen Therapeutics Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | HK$9.58B | 15.02 | 4.50% | 4.28% | -7.59% | -41.42% | |
58 Neutral | HK$13.98B | -77.24 | -11.81% | ― | 219.26% | 87.63% | |
58 Neutral | HK$24.04B | 73.24 | 8.62% | ― | 48.38% | ― | |
54 Neutral | HK$19.00B | -9.33 | -12.74% | ― | 57.92% | -23.76% | |
53 Neutral | HK$12.51B | -38.53 | -11.43% | ― | 142.64% | 72.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$10.05B | 30.77 | 24.17% | ― | 154.21% | ― |
* Healthcare Sector Average
HK:2171
CARsgen Therapeutics Holdings Ltd.
22.76
6.78
42.43%
HK:1672
Ascletis Pharma, Inc.
16.68
10.00
149.70%
HK:1952
Everest Medicines Ltd.
35.66
-13.29
-27.15%
HK:2157
Lepu Biopharma Co. Ltd. Class H
5.40
0.80
17.39%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
51.70
39.64
328.69%
HK:6826
Shanghai Haohai Biological Technology Co., Ltd. Class H
22.26
-1.20
-5.12%
CARsgen Therapeutics Holdings Ltd. Corporate Events
CARsgen Advances Allogeneic CAR T Programs as EHA Accepts New Data for 2026
Apr 27, 2026
CARsgen Therapeutics said investigator-initiated trial data for its allogeneic CAR T-cell candidates CT0596 and CT1190B have been accepted for poster presentation at the 2026 European Hematology Association congress, underscoring progress in its o...
CARsgen Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority
Apr 10, 2026
CARsgen Therapeutics Holdings Limited has convened its annual general meeting for 22 May 2026 in Shanghai, where shareholders will vote on adopting the audited financial statements for the year ended 31 December 2025 and the accompanying directors...
CARsgen Grants 4.27 Million Share Options Under Post-IPO Incentive Scheme
Mar 9, 2026
CARsgen Therapeutics has granted 4,267,000 share options to 181 grantees under its Post-IPO Share Option Scheme, with an exercise price of HK$13.92 per share and a 10-year exercise period from the grant date. The options vest in four equal annual ...
CARsgen Shares Added to Southbound Stock Connect, Opening Door to Mainland Investors
Mar 9, 2026
CARsgen Therapeutics said its Hong Kong-listed shares have been added to the Southbound trading lists of both the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, effective March 9, 2026. The move allows eligible mainland Chinese ...
CARsgen Narrows 2025 Loss as CAR-T Therapy Sales Grow and Costs Fall
Mar 6, 2026
CARsgen reported revenue of about RMB125.7 million for 2025, mainly driven by sales of its CAR-T therapy zevorcabtagene autoleucel, with revenue recognized on an ex-works delivery basis that can lag behind order intake. The company generated rough...
CARsgen Schedules Board Meeting to Approve 2025 Annual Results
Feb 24, 2026
CARsgen Therapeutics Holdings Limited has scheduled a board meeting for March 6, 2026 to review and approve the Group’s annual results for the financial year ended December 31, 2025. The meeting will also address other corporate matters, sig...
CARsgen to Invest RMB370 Million in New CAR T Manufacturing Base in Shanghai
Feb 13, 2026
CARsgen Therapeutics will invest up to RMB370 million through its subsidiary CARsgen Diagnostics to establish an advanced commercial CAR T-cell manufacturing base in Jinshan District, Shanghai, in partnership with Shanghai Jingong Enterprise Devel...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.